Ranbaxy Woes Continue With 33-Product Import Alert
This article was originally published in The Pink Sheet Daily
Executive SummaryFDA restricts 26 finished drugs and seven API because of GMP violations.
You may also be interested in...
Baxter resolves US plant’s GMP whistleblower allegations for just $18m, a bargain compared to the $750m GlaxoSmithKline paid in 2010 and the $500m Ranbaxy paid in 2013. One reason: it was more narrowly focused.